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1. Introduction
In multicellular organisms the regulation of growth, development and metabolic homeostasis
involves extensive intercellular communication. This is achieved by diverse endocrine signal
molecules that often address intracellular receptors which regulate gene expression in a ligand-
dependent manner. Proteins involved in up- or down-regulation of gene expression are termed
transcription factors. It is estimated that about 10 % of the human genome encodes proteins of
this family [1]. An important class of transcription factors are nuclear receptors (NRs). So far,
48 different NRs have been identified in humans. However, due to alternative splicing the
number of different functional NRs is substantially larger [2]. Similar to other protein families
(e.g. G protein-coupled receptors) a unified nomenclature system has been established in order
to overcome problems due to multiple names for the same gene [3].
NRs recognize and bind small molecules that comprise, for example, steroid and thyroid
hormones, vitamins as well as fatty acids and their derivatives [4]. In fact, for only about half
of human NRs an endogenous ligand has been identified so far. The involvement of several
members of the NR superfamily in various diseases has made this class of transcription factors
highly attractive for pharmaceutical industry. As described below, several members of the NR
family are already addressed by drugs and more receptors are under investigation [5].
Understanding nuclear receptor function requires knowledge of the NR structure. The
composition of nuclear receptors is modular and involves 5-6 domains with distinct functions
(Figure 1). Evolutionary most conserved domains are the DNA-binding domain (DBD) and
the ligand-binding domain (LBD). Other domains show a considerable variation in length and
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sequence such as the N-terminal domain, the hinge region - connecting DBD and LBD - as well
as the C-terminal domain.
The N-terminal domain (NTD) possesses a ligand-independent activation function 1 (AF-1)
and contains several post-translational modification sites [6, 7]. The NTD size may vary
considerably, ranging from 23 to 602 residues. Although no X-ray crystal structures of this
domain are available, circular dichroism studies have indicated the presence of some secon‐
dary structures upon posttranslational modifications [8]. The DBD domain consists of about
70 highly conserved amino acids and contains two zinc-finger motifs which are essential for
DNA binding [9]. The DBD organisation allows binding to specific DNA sequences (responsive
elements) [9]. The core region of the response elements is organised as hexameric motif with
the consensus sequence 5’-AGGTCA-3’ [8]. The number of motifs as well as their organisation
and spacer length between the repetitive elements and the flanking regions affect the specificity
of NR binding [10, 11]. A typical response element presents two repetitions of the core motif
that can be organised in inverted, everted or direct repeats [12].
Figure 1. Assembly of nuclear receptor and their interaction partners. A: Nuclear receptors are composed of several
domains. Main domains are i) the N-terminal domain (NTD) of variable length that carries the ligand-independent ac‐
tivation function 1 (AF-1), ii) the DNA-binding domain (DBD) that binds to the response elements in the promoter re‐
gion of target genes and iii) the ligand-binding domain (LBD) that harbours the ligand-binding pocket (LBP), the
ligand-dependent activation function (AF-2) as well as a binding site for coregulatory proteins (CoR) and other nuclear
receptors.Most nuclear receptors bind as dimers to their response elements. B: X-ray crystal structure (PDB code 3DZY
of the PPARγ (violet) and RXRα (orange) DBD and LBD (cartoon representation) bound to DNA (CPK representation).
Structure was solved in complex with NR agonists (shown in CPK representation) rosiglitazone (PPARγ) and 9-cis ret‐
inoic acid (RXRα) as well as coactivator peptides (blue ribbons).
The second large domain is the ligand-binding domain (LBD) that is connected to the DBD via
the hinge region. As the name already indicates, the LBD is capable to bind small molecules
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in its ligand-binding pocket (LBP) [12]. In addition, the LBD carries the ligand-dependent
activation function 2 (AF-2), located on its C-terminal helix (helix 12, H12) [13]. In addition,
the LBD contains a dimerisation motif that allows binding of other NRs and an interaction site
for co-regulatory proteins that are important for activation and inhibition of target gene
expression [14, 15]. The LBD comprises about 250 amino acids and is mainly composed of α-
helices, arranged in a so-called three-layered helix sandwich. The ligand-binding pocket is
found between both outer layers. Size and amino acid composition of the LBP differ substan‐
tially among different NRs resulting in LBP volumes ranging between 100 Å3 (ERRα) and 1300
Å3 (PPARγ) [13, 14]. In some cases, for example NURR1, no ligand-binding pocket is present,
suggesting a ligand-independent mechanism of action [23].
Ligand-binding to the LBP modulates the conformation of helix 12 (AF-2). Agonists induce
AF-2 to adopt a helical conformation that covers the ligand-binding pocket like a lid. By this
process, a binding site for co-activator proteins is generated. These bind to the receptor via
their nuclear receptor interacting domain (NRID) which contains a highly conserved LxxLL
motif (L = leucine, x = any residue) [15]. Several co-activators (e.g. SRC-1) contain an intrinsic
histone acetyltransferase function which results in decondensation of the chromatin at the
promoter region, thereby improving accessibility of further transcription factors. In addition,
co-activators recruit other proteins with histone modifying capabilities as well as proteins of
the basal transcription machinery. Eventually, these processes initiate target gene expression.
In contrast, NR antagonists displace H12 from the active conformation, which is often
associated with partial unfolding of the helix. This event induces binding of co-repressor
proteins to the receptor. Similar to co-activators, further proteins are recruited that lead to
chromatin condensation (e.g. by histone deacetylases), thereby silencing gene expression.
Figure 2. Examples for approved drugs targeting nuclear receptors.
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Besides other drug target classes such as G protein-coupled receptors, ion channels or receptor
tyrosine kinases, nuclear receptors represent another major receptor target class. As of 2011,
76 approved drugs targeting 17 nuclear receptors were available (See Figure 2 for selected
examples) of which several generate more than 1 billion dollar sales each year [5]. In this
chapter we will highlight selected NRs which are targeted by approved drugs and provide
insight into current efforts to address additional receptors using small molecules. A focus will
be on novel mechanisms of receptor inhibition as shown by co-activator-binding inhibitors. In
addition, currently used methods for studying nuclear receptor function in drug discovery are
described.
2. Pharmaceutically relevant nuclear receptors and their drugs
Most nuclear receptors addressed by approved drugs belong to the subfamilies 1 (thyroid
receptor like receptors) and 3 (estrogen receptor like receptors). Main indication areas are
cancer, hormone replacement and metabolic diseases.
An NR that is targeted by both, agonists and antagonists, is the estrogen receptor (ER),
belonging to the steroid hormone receptors. Two ER forms exist, called α and β (NR3A1,
NR3A2). An endogenous ligand of both ERs is the steroid hormone 17β-estradiol. While
estradiol preferentially binds to the α-form (Figure 3A & C), the third estrogen produced in
humans (estriol) favors the β-form. Both ERα and ERβ bind as homodimers to their response
elements. The natural ligand estrogen is also applied in hormone replacement therapy.
Of main pharmaceutical relevance is ERα. In the majority of breast cancers (~70 %), ERα is
overexpressed in breast tissue (ERα-positive cancer). Since the natural ligand estradiol plays
an important role in breast cancer development and progression, antagonists targeting ERα
have been developed for treatment of ERα-positive breast cancer [16]. A frequently used drug
that addresses ERα is tamoxifen (Figure 2), a potent antagonist of the receptor. Being a prodrug,
tamoxifen requires conversion to the bioactive forms 4-hydroxytamoxifen and N-desmethyl-4-
hydroxytamoxifen in the liver by cytochromes CYP2D6 and CYP3A4. Both metabolites possess
up to 100-fold better affinity to the receptor than the prodrug [17]. Tamoxifen and its metab‐
olites belong to the class of selective estrogen receptor modulators (SERMs), which are
chemically different to the natural ligand estradiol. In breast tissue, tamoxifen metabolites act
as competitive inhibitors of the natural ligand estradiol in the ER ligand-binding pocket, while
in other tissues such as the endometrium, the compounds act as potent ER agonist [18]. This
agonistic effect is problematic as it substantially increases the risk of uterine cancer and
therefore the compound is not used for long-term treatment [27].
Another selective estrogen receptor modulator is the benzothiophene raloxifene which is
applied for treatment and prevention of osteoporosis in postmenopausal women but also for
reducing the breast cancer risk. The compound is not a prodrug like tamoxifen as it already
contains two hydroxyl groups that form hydrogen bonds with the same LBP-residues as the
tamoxifen metabolites. Also a difference is the mechanism of action as raloxifene does not show
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any antitumor activity. Instead, the compound is used for preventing osteoporosis and may
also reduce the incidence of breast cancer in postmenopausal women.
Both SERMs are T-shaped molecules. X-ray crystal structures of estrogen receptor α co-
crystallized with 4-hydroxytamoxifen and raloxifene have revealed the binding mode within
the LBP (Figure 3B & D).The core structure of both compounds is planar and binds in a similar
orientation into the ligand-binding pocket as the natural ligand estradiol (Figure 3A & C).
Several hydrogen bonds shared with the receptor ensure tight binding. Hydrogen bond
formation with the receptor is only possible for the metabolized forms of tamoxifen and
explains why these molecules are much more potent compared to the prodrug. The side chain
protruding from the core structure of tamoxifen metabolites and raloxifene sterically displaces
H12 from the active conformation, resulting in an inactive NR [25, 26].
Figure 3. Protein-ligand interactions in estrogen receptor α (ERα). A: ERα (cartoon representation) in complex with the
natural agonist estradiol (capped sticks representation, carbon atoms in green, oxygen atoms in red). Helix 12 (violet)
is in the active conformation enabling coactivator binding (NRID in blue). B: Antagonist binding (raloxifene) displaces
H12 from the active conformation thereby disrupting the coactivator binding site. C & D: Binding modes of estradiol
(C) and raloxifene (D) within the ERα LBP. Both compounds have an identical hydrogen bond interaction pattern
(black dotted lines). In addition, raloxifene forms a salt bridge with Asp351.
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Another member of the nuclear receptor superfamily targeted by drugs is the androgen
receptor (AR, NR3C4). Natural AR ligands are the androgens testosterone or dihydrotestos‐
terone (Figure 4A), both activating the receptor. AR is expressed in several tissues of which
the prostate and adrenal gland are representing the main expression sites [19]. Besides its role
in sexual differentiation in utero and male pubertal genesis, AR is involved in maintenance of
libido, spermatogenesis, muscle mass and strength, bone mineral density and erythropoiesis
[20]. Several diseases such as prostate cancer or androgen insensitivity syndrome have been
linked to AR [19]. For treatment of prostate cancer hormone deprivation using chemical
(luteinizing-hormone-releasing hormone analogues, LHRHa) or surgical castration is a
standard therapy that is initially effective in reducing the number of circulating tumor cells.
But almost invariably resistance emerges after few years. This type of cancer is then referred
to as castration-resistant prostate cancer (CRPC) with poor prognosis. By virtue of AR gene
overexpression and amplification as well as mutations within the AR gene, androgen receptor
activity is upregulated in CRPC. In order to treat CRPC, AR antagonists, also termed anti-
androgens, have been developed.
Both steroidal and non-steroidal AR antagonists have been developed. Low efficacy and
hepatotoxicity as well as cardiovascular side effects and problems with libido and potency
have limited the use of steroidal antiandrogens. These side effects are largely due to the effect
of the drugs on other nuclear receptors recognizing steroid hormones (e.g. progesterone
receptor, or glucocorticoid receptor). Non-steroidal anti-androgens (NSAA), which have been
introduced about 25 years ago, are mainly used in advanced and metastatic prostate cancer
treatment [21]. First generations of NSAAs were flutamides and their derivatives bicalutamide
or nilutamide, which are chemically related compounds. The mode of action of these drugs is
to compete with the natural ligand for AR binding and thereby antagonizing the receptor and
inhibiting tumor growth. While flutamide is usually used in combination with LHRH-a,
bicalutamide is also applied as monotherapy. In contrast to steroidal anti-androgens, side
effects due to binding to other steroid hormone receptors are less severe.
Enzalutamide (Figure 2), introduced in 2009, is a second generation NSAA used in treatment
of CRPC. Besides competing with the natural ligands, the drug also reduces nuclear translo‐
cation and, as a consequence, DNA binding of the receptor [22]. Enzalutamide prolongs life
of cancer patients, who did not receive chemotherapy before, with only a few registered side-
effects [23]. However, in many CRPC-patients resistance occurs after several months of
treatment which had been linked to a mutation within the LBD [24].
In order to overcome resistance problems and to establish therapeutics not targeting the ligand-
binding pocket, an alternative approach is to address the protein-DNA interactions of the AR
by molecules binding to the DBD. By now several studies have already reported successful
identification of compounds targeting DBD of enzalutamide-resistant ARs [25, 26].
Another example for receptors targeted by already approved drugs is the group of peroxisome
proliferator-activated receptors (PPARs). Three PPAR subtypes have been identified: PPARα,
PPARδ (also termed PPARβ) and PPARγ. Unlike ER, all PPARs form heterodimers with the
retinoid X receptor. Another difference to steroid hormone receptors is a considerably larger
LBP. Natural ligands of PPARs include various fatty acids and eicosanoids. Some compounds
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specifically address single PPAR subtypes. For example leukotriene B4 activates only
PPARα while a variety of prostaglandins are ligands for PPARγ.
All currently approved PPAR drugs target α and γ subtypes and are used in treatment of
metabolic diseases. PPARα is addressed by fibrates, e.g. clofibrate or gemfibrozil (Figure 2).
Upon receptor activation, a large set of genes is upregulated, including many enzymes
involved in lipid metabolism, e.g. lipid transport, oxidation, lipogenesis or cholesterol
transport [27]. Compounds of the thiazolidinedione class have been developed for targeting
the subtype PPARγ (e.g. rosiglitazone, pioglitazone, troglitazone). Rosiglitazone and piogli‐
tazone are used in treatment of type II diabetes, both activating PPARγ and thereby increasing
the sensitivity of adipocytes to insulin which lowers glucose blood levels. Due to liver toxicity,
troglitazone has been completely withdrawn from the market.
Another class of PPAR-addressing molecules has been introduced recently. The so-called
glitazars are dual PPAR agonists, activating PPARα and PPARγ. In 2013, the first glitazar
(saroglitazar) was approved as drug in India while other glitazar research programs have been
Figure 4. Protein-ligand interactions in androgen receptor (AR). A: AR in complex with testosterone (capped sticks
representation) and coactivator peptide (blue). H12 is shown in violet. B: AR in complex with small molecule (AV6)
bound to AF-2 site. C: AR in complex with flufenamic acid bound to BF-3 site. D & E: Binding modes of AV6 (D) and
flufenamic acid (E) within AF-2 and BF-3 pockets (shown as surface). AV6 shares a hydrogen bond with the receptor
as indicated by the white dotted line.
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discontinued due to safety reasons. Saroglitazar (Figure 2) is used for treatment of diabetic
dyslipidemia and hypertriglyceridemia.
Most nuclear receptors are addressed due to their direct involvement in a disease. However,
some members of the NR superfamily are interesting because of their involvement in drug
metabolism. This process comprises three phases that involve compound modification (e.g.
oxidation by cytochrome P450 enzymes), coupling reactions with hydrophilic substances
(e.g. glucuronic acid, glycine) and finally excretion of the metabolised molecules from the cell
via transporter proteins. Both, pregnane X receptor (PXR) and the constitutive androstane
receptor (CAR), are mainly expressed in liver and intestine and are responsible for ligand-
dependent induction of gene expression of proteins involved in all phases of drug metabolism
[50]. Due to their ability to bind structurally and chemically diverse molecules, including many
prescription drugs and other synthetic compounds that enter the human body, CAR and PXR
are also termed xenosensors [28].
Comparing both receptors, PXR is most promiscuous and recognizes a large set of prescription
drugs, among them calcium channel blockers, statins, antidiabetic drugs, HIV protease
inhibitors and also artemisinin and its derivatives [29, 30]. PXR X-ray crystal structures have
unravelled the basis for the pronounced ligand promiscuity of the receptor. The receptor LBD
deviates from the canonical NR fold (H6 unfolded, H7 broken, long H1-H3 loop which is part
of LBP), resulting in a large LBP with considerable plasticity that adapts to structurally and
chemically diverse molecules [31, 32]. The molecular weight of compounds binding to PXR
varies from 200 to more than 800 Da. Rifampicin is the largest known PXR agonist.
Similar to PXR, CAR binds structurally diverse ligands, however the spectrum is less pro‐
nounced since the ligand-binding pocket is much smaller and less flexible [33]. Known ligands
are 5-androstan-3-ol and 5-androst-16-en-3-ol as well as pregnanedione [34-36]. Also prescrip‐
tion drugs such as artemisinin and meclizine have been identified as CAR ligands, (meclizine
acts as inverse agonist) [29, 37]. Besides direct activation upon ligand binding, CAR can be also
indirectly induced in a yet unknown manner by compounds such as phenobarbital or pheny‐
toin, respectively [38].
3. Current status of NR drug discovery research
3.1. Other nuclear receptors as potential drug targets
Current NR research not only continues to develop improved modulators for receptors already
targeted by approved drugs as described before, but also intends to address other NRs that
have been identified to be involved in various diseases with agonists or antagonists. Repre‐
sentative examples for these nuclear receptors are the liver X receptor (LXR), farnesoid X
receptor (FXR) or PPARδ.
LXR exists in two isoforms: LXRα (NR1H3) and LXRβ (NR1H2). While LXRα is mainly
expressed in the liver, LXRβ is ubiquitously expressed. Endogenous LXR ligands are oxyster‐
ols, oxigenated derivatives of cholesterol (e.g. 27-hydroxycholesterol, cholestenoic acid) and
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cholic acid [39]. Both isoforms are involved in transcriptional control of genes involved in
uptake, transport, efflux and excretion of cholesterol in a tissue-dependent manner as well as
inflammatory responses in the CNS [40, 41]. LXRα and LXRβ bind as heterodimers (RXRα) to
the response elements of LXR target genes which comprise (among others) ABC transporters,
apolipoprotein A and fatty acid synthase. Therefore, compounds modulating LXR are
considered as potential therapeutics for metabolic and neurodegenerative diseases. Many
small molecules targeting LXR have been identified in the last decades and several have
reached clinical phases [42]. A problem of LXR agonists are adverse effects due to LXRα
activation in the liver, resulting in increased hepatic lipogenesis, hypertriglyceridemia and
liver steatosis. As both isoforms share 77 % sequence homology in DBD and LBD, the identi‐
fication of selective agonists is not a trivial task. Nevertheless, some selective LXRβ agonists
have been reported. The first identified selective agonists (N-acylthiadiazolines) activate the
β-isoform several times more efficient than the α-isoform [43]. A phenylsulfone-substituted
quinoxaline compound has been identified as partial agonist of LXRβ (potent activator in
kidney cells, low induction in liver cells) and revealed poor affinity towards LXRα [44]. Very
recently, LXRβ-selective compounds have been identified using pharmacophore modelling
and shape-based virtual screening which activated LXRβ up to 1.8-fold over the α-isoform [45].
As described above, two members of the PPAR subfamily are already addressed by approved
drugs. Current research also focuses on the third member, PPARδ. Expressed in most meta‐
bolically active tissues, the receptor regulates expression of a set of genes involved in glucose
homeostasis and fatty acid synthesis/storage, mobilization and catabolism [46]. Due to its
physiological functions, agonists of PPARδ are considered as potential therapeutics of the
whole spectrum of metabolic syndromes including diabetes, atherosclerosis and obesity [46].
In addition, PPARδ agonists have been shown to stimulate oligodendrocyte differentiation
and thus are considered as potential therapeutics in demyelinating disorders such as multiple
sclerosis [47].
So far, a large bunch of receptor agonists have been identified that advanced research on this
PPAR subtype and its physiological role [48]. Recently, a benzisoxazole has been identified as
PPARδ-selective agonist with an EC50-value of 4.5 nM as determined using a cell-based assay
[49]. Another example is GW501516, a PPARδ ligand developed by GlaxoSmithKline that has
been identified by combinatorial chemistry and structure-based design [50]. The compound
revealed high affinity and potency against PPARδ while showing a more than 1000-fold
selectivity over PPARα and PPARγ. Despite its favorable effect on the receptor and no toxicity
in human trials, the compound was not developed further. Later studies in animal models
revealed the compound to possess a substantial carcinogenic potential.
Besides the discovery of receptor-selective compounds, the development of dual agonists
activating two PPAR subtypes or pan-agonists activating all members of the PPAR subfamily
is also actively pursued. Although a compound of the glitazar class has recently been approved
as drug, no further compounds have reached so far the market.
Another example of a promising nuclear receptor drug target is the farnesoid X receptor (FXR)
which binds bile acids, the final product of the cholesterol metabolism [51]. Due to the toxic
properties of bile acids their levels have to be tightly regulated. FXR can regulate the bile
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homeostasis by activating other nuclear receptors (such as CAR, PXR and VDR) [52], cell
surface receptors (G protein-coupled bile acid receptor 1), receptor and calcium-gated
potassium channels. FXR signaling is involved in the regulation of intestinal bacterial flora
[53], liver regeneration [54] and - in case of misregulation - to hepatocarcinogenesis [55, 56]).
FXR is considered as a suitable drug target for the treatment of dyslipidemia, atherosclerosis
and cholestatic disorders, and some effort has been spent on identification and development
on agonists [57]. From the already approved drugs, the antiparasitic drug ivermectin has been
identified as a FXR agonist [58]. In spite of some side effects related to trygliceride misbalance,
FXR agonists are able to recover cholestasis and antidyslipidemic effects [59, 60].
3.2. Co-activator-binding inhibitors as a future therapeutic approach?
All currently approved drugs targeting NRs address the ligand-binding pocket. In recent years,
novel approaches for inhibiting NRs have emerged in order to overcome limitations of LBP-
targeting drugs. Problems may be side effects due to displacement of the natural ligand,
thereby disturbing physiological homeostasis, but also limitations of the ligand diversity as
imposed by the shape and composition of the LBP as well as resistance of the receptor due to
mutations [61].
In order to overcome these limitations, non-LBP pockets have been investigated for their
potential to harbour small molecules and thereby modulate receptor activity. In particular,
sites involved in NR-co-activator interactions or receptor-DNA contacts have been investigat‐
ed in detail. The modulation of NR-co-activator interactions has been studied extensively in
recent years and several studies have reported the successful discovery of co-activator binding
inhibitors (CBI) which confirms the applicability of this approach [62]. Nevertheless, the
development of CBIs is challenging due to specificity issues (more than 300 coregulators have
been identified in humans so far) as well as the general conformational flexibility of NRs.
Most studies have concentrated on the co-activator binding site (AF-2 site). Several alternate
mechanisms have been proposed for explaining the deleterious effects of interference with
AF-2. Besides inhibition of co-activator binding , this may involve corepressor recruitment,
increase on the NR turnover levels, blockage of the dimer formation, or inhibition of interac‐
tions between the N- and C-terminal domain [8].
Because of the anti-androgen resistance phenomenon of prostate cancer [63], modulators
addressing the AF-2 site have attracted attention. The effect of AR co-regulator binders is
considered to function by inhibition of the N/C interaction that occurs between AF-1 and AF-2
which is considered as crucial for stabilization of the receptor-ligand complex in the active
conformation [61]. Interestingly, AR not only binds co-activators carrying the LxxLL motif but
also the more bulky FxxLF motif. X-ray crystal structures of the AR LBD revealed the presence
of deep pockets at the AF-2 site, enabling accommodation of the large FxxLF side chains. Not
only synthetic peptides, based on a pyrimidine core, were able to selectively displace AR co-
activator molecules, as corroborated by FRET assays, and interfere with transcription activa‐
tion [64], but also small molecules have been identified to disrupt co-activator binding using
a virtual screening campaign with subsequent experimental validation (Figure 4B & D) [65].
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Another receptor for which AF-2 binders have been identified is the thyroid hormone receptor
(TR). TR subtypes are a target for treatment of hyperthyroidism or cardiac arrhythmias. The
co-activator binding site of TRβ has been successfully targeted using macrolactam-constrained
co-activator peptides [66]. Another approach to address TRβ is the use of suicide inhibitors.
The proposed pro-drug, DHPPA (or 3-(dibutylamino)-1-(4-hexylphenyl)-propan-1-one)) is
able to interact with the AF-2 surface in a similar way as he co-activator SRC-1 [67].
Also the xenosensor PXR has been investigated for inhibition by CBIs. As described before,
the receptor has not been addressed for specific treatment. Instead, PXR AF-2 inhibitors are
intended to prevent premature drug metabolism, leading to prolonged half-lifes that may
result in lower dosages and less side effects. In addition, PXR antagonists may be applied to
prevent drug-drug-interactions in patients treated with combination therapies or multimorbid
patients exposed to a variety of drugs. Antibiotics such as fluconazole, enilconazole and
ketoconazole inhibit PXR, resulting in reduced expression levels of CYP3A4 and MDR1 [68].
It has been shown that the compounds inhibit PXR-SRC-1 interactions by binding to the AF-2
site using site-directed mutagenesis [69]. Based on the proposed binding mode and the
resulting receptor-ligand interactions, a pharmacophore has been generated [70]. In a follow-
up study the pharmacophore has been utilized for the identification of several small molecule
antagonists of PXR, including the FDA approved prodrug leflunomide [71].
In addition to the AF-2 site, other regions of the LBD also have been successfully targeted by
small molecules that modulate the interaction of the receptor with co-activator proteins.
Recently, a small hydrophobic pocket formed by amino acids located on helix 1, the H1-H3
loop as well as helix 9 has been identified on the AR surface (termed BF-3 site) to be addressable
by small molecules [67]. By testing a set of approximately 55,000 compounds from various
sources using fluorescence polarisation and X-ray crystallographic screenings, several small
molecules such as 3,3’,5-triiodothyroacetic acid, T3 or flufenamic acid have been identified to
bind to BF-3 (Figure 4C & E) [67]. The BF-3 site is conserved among steroid hormone receptors
such as progesterone receptor, mineralocorticoid receptor and glucocorticoid receptor,
suggesting that a similar approach could also lead to the identification of CBIs against these
receptors [72]. Compounds binding to BF-3 seem to allosterically interfere with co-activator
binding to the AF-2 site [73]. In the last years, several studies have reported the successful
discovery of additional small molecules targeting the BF-3 pocket. Using virtual screening in
combination with biochemical and cell-based tests, a set of structurally diverse AR inhibitors
has been identified. Binding to BF-3 has been confirmed by solving the X-ray crystal structure
of the receptor-ligand complex. In a follow-up study, one of these molecules was further
developed to AR inhibitors with IC50 values at low micromolar range [74]. Subsequently the
crystal structure of the AR in complex with 2-((2-phenoxyethyl)thio)-1H-benzimidazole
confirmed molecule binding at the BF-3.
4. Methods to assess ligand binding and/or activation of nuclear receptors
In the last thirty years several molecular and cell biology standard methods have been applied
to investigate nuclear receptor functions and regulations [75]. For example cDNA cloning has
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been used to identify the genes encoding orphan nuclear receptors. In order to discover
hormone-response elements, electrophoretic mobility shift assays (EMSA) and chromatin-
immunoprecipitation (ChIP) have been applied as well as different GST pull-down assays
[76-78].
To investigate the biological effect of a compound, a variety of binding assays have been
developed. A standard ligand-binding how a ligand competes with a known labeled ligand
in binding to the receptor [79]. In recent years a variety of non-radioactive activity assays such
as biochemical-based fluorescent polarization and time-resolved fluorescence assays have
been developed [80]. Detailed analyses of the macromolecular interaction of ligand binding,
including affinity- and binding kinetics, have been performed by the surface plasmon reso‐
nance (SPR) technology (see also below) [81].
Due to their relevance as therapeutic targets [83] the pharmaceutical industry prioritised the
development of novel assay systems that allowed to accelerate the throughput and the
screening of large compound collections. Therefore, a couple of academic laboratories as well
as pharmaceutical and biotech companies have spent much effort in the development of high-
throughput screening compatible screening assays in the last decade [84, 85]. These efforts led
to modified methodologies with higher throughput and less variability. A couple of NR
screening campaigns have used smal molecule libraries such as Sigma-Aldrich LOPAC,
Biomol and Tocris/TimTec bioactive collection and U.S. Food and Drug Administration 1 and
2 collection [86]. Despite the fact that most of the assays have been designed for certain targets
the principles could be expanded to any NR, making these assay formats accessible to drug
discovery applications.
In the following, a selection of relevant biochemical and cell-based assays as well as in silico
methods is presented that is frequently used in NR research, both in academia and pharma‐
ceutical industry.
4.1. Transactivation assays
The most common test systems for nuclear receptor activation are cell-based transactivation
assays. These assays rely on the potential of nuclear receptors to activate transcription upon
ligand binding [87, 88]. In general, this is achieved by transfection of cells with an expression
vector for the receptor and a reporter vector that contains the binding site for the receptor and
also encodes for a protein that, when incubated with the appropriate substrate, result in a
detectable signal.
Standard protocols involve transient transfection of the receptor and a response element-
reporter gene construct [89]. The general advantage of these cell-based assays is that they allow
screening of large compound libraries in a reproducible fashion [85]. Until now many cell lines
have been described as possible recipients of these vectors, including CHO, HuH7, MCF-7,
HEK293, HepG2 and Caco-2 cells [90]. Using transient transfection systems a couple of
investigators identified activators for various nuclear receptors [62].
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4.2. Corregulator-recruitment (mammalian two-hybrid, CARLA)
An alternative transactivation assay system is the mammalian two-hybrid system. This assay
represents a powerful approach for detecting protein-protein interactions in cells, which has
evolved from the original two-hybrid system into a method for identifying NR ligands. The
system is based on the finding that co-activators and co-repressors are involved in the
regulation of NR function. Following ligand binding, many NRs perform a conformational
change and form a specific co-activator binding pocket, which permits co-activator binding.
In the mammalian two-hybrid approach, chimerical receptors containing the LBD of interest
are fused to the DBD of the yeast transcription factor GAL4, which binds to specific NR
response elements. The interaction between the NR and its co-activator is detected using a
reporter gene containing multiple copies of the GAL4 upstream activating system.
Examples are mammalian two-hybrid assays consisting of the LBD of human CAR and co-
activator SRC-1 fused to GAL4 DBD. In this assay the ligand binding enhances the interaction
between LBD and SRC-1, which is detected by the reporter gene activity [91]. Using a similar
assay a set of agonists and inverse agonist were identified to bind to the human CAR even if
some results were contradictory [92, 93]. It was speculated that the use of truncated chimerical
receptors resulted in subtle conformational changes and unspecific protein-protein interac‐
tions [90], which led to the conclusion that utilization of full-length receptors is more sensitive
and better reflects the in vivo situation [85].
An assay type that allows monitoring of co-activator recruitment is the Co-Activator-depend‐
ent Receptor Ligand Assay (CARLA) [100]. CARLA is based on the principle that ligand-
binding stimulates interaction between the NR and a co-activator protein which is part of the
normal pathway for transcriptional activation. Technically, CARLA is a GST pull-down assay
using a GST-receptor fusion protein and a labelled co-activator. The GST fusion protein is
immobilized on glutathione-sepharose beads and incubated with the co-activator in the
presence or absence of potential ligands. In this setup an actual ligand of the receptor enhances
the interaction of the receptor with the co-activator and thereby increases the amount of co-
activator that is pulled down. In summary, CARLA is a functional binding assay that reports
on the molecular consequence of ligand binding.
Originally, the assay has been developed for the PPARs [94-96]. However, with some modifi‐
cations the assay format can be used for any nuclear hormone receptor and several co-
activators including SRC-1, CBP/p300, Tif2, Rac3, GRIP-1, and RIP140 [97].
4.3. Surface plasmon resonance, biochemical assay formats, AlphaScreen® and LANCE®
Detailed analyses of the macromolecular interaction of ligand-binding including affinity and
binding kinetics is performed by Surface Plasmon Resonance (SPR) [81]. This technology
overcomes the common limitations of indirect non-equilibrium methods due to its high
sensitivity [82]. In the standard SPR approach, only small amounts of receptor protein are
immobilized onto solid phase while different concentrations of the ligand are passed in flow
over the surface. In NR research, SPR has been applied to detect and quantify receptor-DNA,
receptor-receptor, as well as receptor-ligand interactions [81]. In the past it has also been used
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to characterize binding of co-regulators of a variety of nuclear receptors including thyroid
receptor, estrogen and androgen receptor [98-101]. With regard to high-throughput applica‐
tions, a variety of non-cell based assay formats based on the AlphaScreen® or LANCE®
technology have been described [102-104].
AlphaScreen® is a non-radioactive homogeneous proximity assay that relies on energy transfer
between an acceptor and a donor bead brought into proximity via biological interaction. The
donor beads are embedded with a photosensitizer, which converts oxygen to an excited state
upon illumination. If a biomolecular interaction drags an acceptor bead into close proximity
of a donor bead, the excited singlet oxygen will transfer its energy to the acceptor bead leading
to emission of light depending on the fluorophore in the acceptor beads. Each donor bead is
capable of generating up to 60,000 singlet oxygen molecules with a half-life of 0.3 seconds,
allowing measurements in a time-resolved mode and with substantial signal amplification.
The technology can used to rapidly develop high-throughput screening (HTS) assays for NRs
[105-107].
A nuclear receptor AlphaScreen® assay is based on the ligand-activated biomolecular interac‐
tion between NR and its co-activator, followed by the detection of this interaction using
AlphaScreen® compatible reader technology. For many NRs a consensus co-activator peptide
sequence (LxxLL motif) is sufficient for the interaction of the agonist-bound receptor with LBD.
The detection can be realised by various strategies depending on the nature of the involved
binding partners. Rouleau & Bossé (2006) described such an AlphaScreen® Assays, for estrogen
receptor α (ERα) and retinoic acid receptor γ (RARγ) [107]. Other configurations depending
on the availability of respective detection reagents, tags and beads are also possible which have
already been described for e.g. FXR receptor [105].
Another well validated assay type for studying NR-ligand interactions is based on the
LANCE® Technology [102]. In the LANCE® assay, a signal is generated when a donor molecule
labelled with chelate europium (Eu) gets into proximity of the acceptor molecule labelled with
allophycocyanin (APC). When a biological interaction brings the donor and the acceptor into
close proximity, excitation of the Eu-chelate at 340 nm allows Fluorescence Resoncance Energy
Transfer (FRET) to the acceptor APC molecule resulting in fluorescence emission at 665 nm.
Long stakes shift and excited-state lifetimes of Europium complex (hundreds of microseconds)
warrant Time-Resolved FRET (TR-FRET) analysis.
In LANCE® nuclear receptor assays the same biomolecular interactions between the ligand
binding domain and the NR box are addressed. In principle different binding partners can be
used depending on their stability and availability: Examples for combinations are: i) Interac‐
tion between agonist-bound receptor or receptor LBD and LxxLL motif-containing peptide
and/or ii) interaction between an apo- or holo-receptor and the co-repressor interaction
domain.
There are a few examples in literature where LANCE assays based on the interaction between
receptor and co-activator-derived peptide have been applied [108-110]. Most of the assays
reported involve the interaction of biotinylated LxxLL peptides and a tagged receptor LBD.
The complex formation is detected using Eu-labelled antibody and APC-labelled streptavidin.
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A large variety of Lance Eu- and APC-labelled reagents is commercially available which allow
the capture of differently tagged receptors and coactivators [111]. A great advantage of
applying the LANCE technology is the long signal stability, which can be more than 48 h.
4.4. Identification of NR modulators using in silico methods
Besides experimental approaches, computational methods have also been extensively applied
in order to identify novel agonists or antagonists. The availability of LBD crystal structures
allows employment of structure-based virtual screening techniques, for example molecular
docking of virtual compound libraries. If the desired NR structure is not available, homology
modeling techniques can be used to obtain structural data. Since the LBD structure is highly
conserved this approach often results in high-quality protein models.
Once LBP-bound ligands have been co-crystallized, further methods such as pharmacophore-
based searches can be applied that make use of specific protein-ligand interactions. The method
is also often used as filtering step to reduce the number of compounds to be docked when
applying structure-based virtual screening techniques. In any case, a virtual hit requires
experimental investigation for validating its modulating effect on the nuclear receptor.
Many studies have reported the successful application of virtual screening approaches for the
identification of NR agonists and antagonists, thereby confirming the suitability of these
methods. Besides crystal structure data, also homology models have been utilized for the
identification of NR agonists as described for the glucocorticoid receptor (GR) and the
constitutive androstane receptor (CAR) that were modeled on the basis of the solved crystal
structure of progesterone receptor (GR model) or PXR and VDR (CAR model), respectively
[112, 113].
5. Final considerations
Nuclear receptors are an important protein family involved in many physiological processes.
So far, several NRs have been successfully addressed by drugs in order to treat various
diseases. Despite significant progress in the understanding of the physiological role of several
NRs, the function of many receptors is not well understood which is mainly due to missing
information of endogenous ligands. Since only a proportion of receptors are addressed by
drugs, there is a tremendous potential for future drug discovery campaigns. The existence of
a pronounced ligand-binding pocket renders many receptors addressable to drug-like
molecules. The availability of alternative areas addressable by small molecules, for example
protein-protein interaction sites on the NR surface, suggests further possibilities for modulat‐
ing the function of NRs. In order to study NR function and to identify novel receptor modu‐
lators, a large set of experimental and computational methods has been developed and
successfully applied in many research projects.
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